Literature DB >> 32259085

The Brain-Heart Axis: Alzheimer's, Diabetes, and Hypertension.

Andrew S Riching1,2, Jennifer L Major1,2, Pilar Londono3, Rushita A Bagchi1,2.   

Abstract

Alzheimer's disease (AD) is a debilitating neurodegenerative disorder affecting millions worldwide. Currently, there are only four approved treatments for AD, which improve symptoms modestly. AD is believed to be caused by the formation of intercellular plaques and intracellular tangles in the brain, but thus far all new drugs which target these pathologies have failed clinical trials. New research highlights the link between AD and Type II Diabetes (T2D), and some believe that AD is actually a brain specific form of it termed Type III Diabetes (T3D). Drugs which are currently approved for the treatment of T2D, such as metformin, have shown promising results in improving cognitive function and even preventing the development of AD in diabetic patients. Recent studies shed light on the relationship between the brain and cardiovascular system in which the brain and heart communicate with one another via the vasculature to regulate fluid and nutrient homeostasis. This line of research reveals how the brain-heart axis regulates hypertension and diabetes, both of which can impact cognitive function. In this review we survey past and ongoing research and clinical trials for AD, and argue that AD is a complex and systemic disorder which requires comprehensive approaches beyond the brain for effective prevention and/or treatment.
Copyright © 2019 American Chemical Society.

Entities:  

Year:  2019        PMID: 32259085      PMCID: PMC7088943          DOI: 10.1021/acsptsci.9b00091

Source DB:  PubMed          Journal:  ACS Pharmacol Transl Sci        ISSN: 2575-9108


  6 in total

1.  Diabetes and its Complications.

Authors:  Simon Matoori
Journal:  ACS Pharmacol Transl Sci       Date:  2022-07-12

2.  Markers of kidney function, genetic variation related to cognitive function, and cognitive performance in the UK Biobank.

Authors:  Erin L Richard; Linda K McEvoy; Ian J Deary; Gail Davies; Steven Y Cao; Eyal Oren; John E Alcaraz; Andrea Z LaCroix; Jan Bressler; Rany M Salem
Journal:  BMC Nephrol       Date:  2022-04-27       Impact factor: 2.585

Review 3.  Oestrogenic Regulation of Mitochondrial Dynamics.

Authors:  Siavash Beikoghli Kalkhoran; Georgios Kararigas
Journal:  Int J Mol Sci       Date:  2022-01-20       Impact factor: 5.923

Review 4.  Hybrid total-body pet scanners-current status and future perspectives.

Authors:  Vanessa Nadig; Ken Herrmann; Felix M Mottaghy; Volkmar Schulz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-10-14       Impact factor: 9.236

5.  Cognition impairment and risk of subclinical cardiovascular disease in older adults: The atherosclerosis risk in communities study.

Authors:  Dongze Li; Yu Jia; Jing Yu; Yi Liu; Fanghui Li; Wei Zhang; Yongli Gao; Xiaoyang Liao; Zhi Wan; Zhi Zeng; Rui Zeng
Journal:  Front Aging Neurosci       Date:  2022-07-27       Impact factor: 5.702

6.  Metformin as a potential therapeutic for neurological disease: mobilizing AMPK to repair the nervous system.

Authors:  Sarah Demaré; Asha Kothari; Nigel A Calcutt; Paul Fernyhough
Journal:  Expert Rev Neurother       Date:  2020-12-04       Impact factor: 4.287

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.